This preliminary program is subject to change.

Engineering Advances in Cancer Treatment


Description:
Cancer is a group of diseases characterized by genetic and other abnormalities leading to an imbalance between cell growth and programmed cell death (apoptosis). Even with advances in broad-spectrum and targeted (antibody-based) therapeutics, successes against this challenging disease remain few and highly focused on particular cancers. Engineers have a significant role to play in advancing the treatment of cancer from the genetic to the systemic scale and across the experimental-computational spectrum. Keys to these contributions are recognition of the clinical state-of-the-art, as well as constraints, defining and limiting potential interventions. Starting from this discussion, speakers from academia, the government, and industry will discuss challenge problems and potential solutions to understanding, analyzing, and treating cancer.

Sponsor:
Biomedical Applications of Chemical Engineering
Co-Sponsor(s):
Engineering Fundamentals in Life Science (15d)


Chair:
Robert Parker
University of Pittsburgh
Department of Chemical and Petroleum Engineering
Pittsburgh, PA 15261
Email: rparker@engr.pitt.edu

Co-Chair:
Neil S. Forbes
University of Massachusetts
Chemical Engineering
159 Goessmann Hall
Amherst, MA 01003
Fax Number: 413 545-1647
Email: forbes@ecs.umass.edu


Papers:
Cancer Cell Migration in 3D
Stephanie I. Fraley, Johns Hopkins University; Yunfeng Feng, Washington University; Pei-Hsun Wu, Johns Hopkins University; Gregory Longmore, Washington University; Denis Wirtz, Johns Hopkins University
Engineering Chimeric Antigen Receptors Targeting an Endogenous Murine Tumor Associated Antigen
Cary F. Opel, Massachusetts Institute of Technology; Matthias T. Stephan, Fred Hutchinson Cancer Research Center; K. Dane Wittrup, Massachusetts Institute of Technology
Genetically Modified Bacteria Actively Secrete Recombinant Protein Biomarker for Early Detection of Solid Tumors
Jan Panteli, University of Massachussetts Amherst; Britanny Forkus, University of Massachussetts Amherst; Neil S. Forbes, University of Massachusetts
A Decision Tool for the Design of Optimal Personalised Chemotherapy Protocols for the Treatment of Acute Myeloid Leukaemia (AML)
Eleni Pefani, Imperial College of London; Nicki Panoskaltsis, Northwick Park Hospital; Athanasios Mantalaris, Imperial College; Michael C. Georgiadis, Imperial College London; Efstratios N. Pistikopoulos, Imperial College London, Centre for Process Systems Engineering
Pharmacokinetic/Pharmacodynamic Model Predicts the Response to Cancer Therapeutics Targeting VEGF
Stacey D. Finley, Johns Hopkins University, School of Medicine; Aleksander Popel, Johns Hopkins University, School of Medicine
An Integrated Systems-Based Modelling Framework for Investigating the Effect of Anticancer Drugs On Solid Tumours
Cong Liu, Imperial College London; J. Krishnan, Imperial College London; Xiao Yun Xu, Imperial College London
Development and Characterization of Novel, Micelle-Based Parthenolide Delivery Systems
Michael Baranello, University of Rochester; Hannah Watkins, University of Rochester; Craig Jordan, University of Rochester Medical Center; Danielle Benoit, University of Rochester